This article was originally published in The Gray Sheet
Plans to repurchase up to 200,000 shares of common stock "in the open market from time to time," according to a July 23 press release. The shares would constitute up to 3.6% of the St. Paul, Minnesota cardiac and vascular surgery product maker's approximately 5.6 mil. outstanding shares.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.